COVID-19

[Science Signaling] The authors found that cell fusion caused by the SARS-CoV-2 spike protein induced a type I interferon response and that that cell fusion damaged nuclei and resulted in the formation of micronuclei that were sensed by the cytosolic DNA sensor cGAS and led to the activation of its downstream effector STING.

[MediciNova, Inc.] MediciNova, Inc. announced that the Phase II clinical trial of MN-166 in hospitalized COVID-19 patients at risk for developing acute respiratory distress syndrome has completed enrollment.

[ScienceInsider] Scientists in more than 20 countries have started to gather data for the largest ever vaccine safety project. Members of the effort, called the Global Vaccine Data Network, fruitlessly sought funding after conceiving the project more than ten years ago.

[SyneuRx™ International] SyneuRx™ International announced it has completed enrollment for its Phase II clinical trial evaluating the efficacy and safety of SNB01 ('Pentarlandir’), a novel COVID-19 oral antiviral candidate.

[Science Translational Medicine] The authors used a cell-free expression workflow to rapidly screen and optimize constructs containing multiple computationally designed miniprotein inhibitors of SARS-CoV-2.

[Science Translational Medicine] The authors used a cell-free expression workflow to rapidly screen and optimize constructs containing multiple computationally designed miniprotein inhibitors of SARS-CoV-2.